This inventor holds 1 USPTO granted patent. Top assignee: Obigen Pharma, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Kuan-Cheng Shen: Innovator in Botulinum Toxin Research
Introduction
Kuan-Cheng Shen is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of botulinum toxin formulations. His innovative work has the potential to enhance safety and efficacy in medical treatments.
Latest Patents
Kuan-Cheng Shen holds a patent for a "Botulinum toxin type A complex, and formulation thereof and usage method therefor." This invention relates to a botulinum toxin type A complex that includes components such as HA70, HA17, HA33, NINH, and BoNT/A1. The complex has a molecular weight ranging from 740-790 kDa. Compared to existing botulinum toxin complexes, this invention is smaller in molecular weight, offers higher safety, and maintains a comparable treatment effect.
Career Highlights
Kuan-Cheng Shen is associated with Obigen Pharma, Inc., where he continues to advance his research and development efforts. His work is pivotal in the ongoing evolution of botulinum toxin applications in various medical fields.
Collaborations
Some of his notable coworkers include Tzu-Wen Tsau and Yung-Kai Wang, who contribute to the innovative environment at Obigen Pharma, Inc.
Conclusion
Kuan-Cheng Shen's contributions to botulinum toxin research exemplify the impact of innovation in biotechnology. His patented work not only enhances treatment safety but also opens new avenues for medical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile